Get the Stockscreener App
0.6817
3.30%
0.0218
After Hours:
.65
-0.0317
-4.65%
Bioaffinity Technologies Inc stock is traded at $0.6817, with a volume of 198.04K.
It is up +3.30% in the last 24 hours and down -17.87% over the past month.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
See More
Previous Close:
$0.6599
Open:
$0.6529
24h Volume:
198.04K
Relative Volume:
0.49
Market Cap:
$4.28M
Revenue:
$5.66M
Net Income/Loss:
$-15.88M
P/E Ratio:
-0.0603
EPS:
-11.3134
Net Cash Flow:
$-10.93M
1W Performance:
-2.46%
1M Performance:
-17.87%
6M Performance:
-48.36%
1Y Performance:
-93.20%
1-Day Range:
$0.65
$0.69
1-Week Range:
$0.6421
$0.7234
52-Week Range:
$0.6121
$13.50
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.6817 | 4.15M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
559.53 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.20 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.89 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
258.03 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
bioAffinity Technologies Inc (BIAF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
bioAffinity, Pictor Collaborate on Asthma and COPD Tests - respiratory-therapy.com
bioAffinity Technologies Highlights CyPath Lung Clinical Framework - TipRanks
bioAffinity Technologies publishes clinical framework to integrate CyPath® Lung into nodule evaluation - TradingView
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung - FinancialContent
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAFW - TradingView
bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAF - TradingView
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance UK
Top QumulusAI (QMLS) Competitors 2026 - MarketBeat
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise - Newswise
bioAffinity Technologies Inc (BIAF) Income Statement - TradingKey
bioAffinity Technologies Inc (BIAF) Cash Flow - TradingKey
bioAffinity Technologies Inc (BIAF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BIAF Stock Gains As CyPath Sales Surge 146% In Q1 - Stocktwits
BIAF|bioAffinity Technologies Inc|Price:0.663|Chg%:-0.005 - TradingKey
bioAffinity Technologies Inc (BIAF) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - The Globe and Mail
bioAffinity Technologies Inc (BIAF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
bioAffinity Technologies Inc (BIAF) Institutional Confidence - TradingKey
What's Driving bioAffinity Technologies' Recent Surge - Kavout | AI
BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD - marketscreener.com
bioAffinity Technologies, Inc. (BIAF) Stock Price, News, Quote & History - Yahoo! Finance Canada
bioAffinity and Pictor partner on diagnostics for asthma and COPD - Yahoo Finance
bioAffinity Technologies Inc (BIAF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAffinity Technologies Inc (BIAF) Fundamental & Financial Data - Stocktwits
bioAffinity Technologies and Pictor Partner to Develop High-Throughput, Cost-Effective Diagnostics for Asthma and COPD – Minichart - Minichart
bioAffinity and Pictor partner on lung inflammation diagnostics - TipRanks
bioAffinity partners with Pictor on asthma, COPD tests - Investing.com
bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics - TradingView
bioAffinity partners with Pictor on asthma, COPD tests By Investing.com - Investing.com Canada
, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD - Business Wire
BIAF|bioAffinity Technologies Inc|Price:0.670|Chg%:+0.002 - TradingKey
Transcript : BioAffinity Technologies, Inc.Special Call - marketscreener.com
Certain Options of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
Certain Warrants of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026. - marketscreener.com
bioAffinity Technologies Initiates New Study for Expanding CyPath Lung Tech - Medical Product Outsourcing
bioAffinity Technologies Inc Warrant 2022- on bioAffinity Financial Disclosures & SEC Filings - TradingView
BIAF stock plunges 77% in 3 months: Should you still hold or sell? - MSN
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - The Globe and Mail
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - AOL.com
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering - AOL.com
bioAffinity reports 200% jump in lung test sales year-over-year By Investing.com - Investing.com South Africa
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues - BioSpace
bioAffinity Technologies’ CyPath Lung Test Sees Rapid Growth - TipRanks
bioAffinity Technologies Sets New Record as CyPath® Lung Sales Double with Over 200% Year-Over-Year Growth in Q2 2026 1 – Minichart - Minichart
bioAffinity reports 200% jump in lung test sales year-over-year - Investing.com
bioAffinity Technologies Q2 CyPath® Lung Sales More Than Double Year‑Over‑Year - TradingView
CyPath Lung demand surges as bioAffinity (BIAF) Q2 2026 test volume more than triples - Stock Titan
bioAffinity Technologies (BIAF) Holds Near Support as Trading Volume Remains ElevatedNaked POC - dars.gov.et
bioAffinity Technologies Sees Record CyPath® Lung Test Sales, Expands Veteran Screening with Philips Partnership - Minichart
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):